MTOR inhibition and the tumor vasculature

Current Angiogenesis

Volumn 1, Issue 1, 2012, Pages 11-19

  Dormond Meuwly, Anne ^a   Dufour, Marc ^a   Demartines, Nicolas ^a   Dormond, Olivier ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Angiogenesis; Cancer; Endothelial cell; MTOR; Proliferation; Rapamycin; Signaling

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; 2 (4 AMINO 1 ISOPROPYL 1H PYRAZOLO[3,4 D]PYRIMIDIN 3 YL) 1H INDOL 5 OL; 2 (4 HYDROXYPHENYL) 4 MORPHOLINOPYRIDO[3',2':4,5]FURO[3,2 D]PYRIMIDINE; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; OXA 01; PALOMID 259; RAPAMYCIN; TEMSIROLIMUS; UNCLASSIFIED DRUG; WYE 354;

ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER THERAPY; PRIORITY JOURNAL; THROMBOSIS; TUMOR VASCULARIZATION;

EID: 84901649132     PISSN: 22115528     EISSN: 22115536     Source Type: Journal    
DOI: 10.2174/2211552811201010011     Document Type: Article

References (78)

1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144(5): 646-674.
2. Weis SM, Cheresh DA. Tumor angiogenesis: molecular pathways and therapeutic targets. Nat Med 2011; 17(11): 1359-1370.
3. Baluk P, Hashizume H, McDonald DM. Cellular abnormalities of blood vessels as targets in cancer. Curr Opin Genet Dev 2005; 15(1): 102-111.
4. Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011; 473(7347): 298-307.
5. Campbell NE, Kellenberger L, Greenaway J, Moorehead RA, Linnerth-Petrik NM, Petrik J. Extracellular matrix proteins and tumor angiogenesis. J Oncol 2010; 2010: 586905.
6. Ebos JM, Kerbel RS. Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nat Rev Clin Oncol 2011; 8(4): 210-221.
7. Heath VL, Bicknell R. Anticancer strategies involving the vasculature. Nat Rev Clin Oncol 2009; 6(7): 395-404.
8. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008; 8(8): 592-603.
9. Carmeliet P, Jain RK. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discov 2011; 10(6): 417-42
10. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005; 307(5706): 58-62.
11. Jiang BH, Liu LZ. PI3K/PTEN signaling in tumorigenesis and angiogenesis. Biochim Biophys Acta 2008; 1784(1): 150-158.
12. Dormond O, Madsen JC, Briscoe DM. The effects of mTOR-Akt interactions on anti-apoptotic signaling in vascular endothelial cells. J Biol Chem 2007; 282(32): 23679-23686.
13. Dormond-Meuwly A, Roulin D, Dufour M, Benoit M, Demartines N, Dormond O. The inhibition of MAPK potentiates the antiangiogenic efficacy of mTOR inhibitors. Biochem Biophys Res Commun 2011; 407(4): 714-719.
14. Guba M, von Breitenbluch P, Steinbauer M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002; 8(2): 128-135.
15. Zhang Q, Bindokas V, Shen J, Fan H, Hoffman RM, Xing HR. Time-course imaging of therapeutic functional tumor vascular normalization by antiangiogenic agents. Mol Cancer Ther 2011; 10(7): 1173-1184.
16. Guba M, Yezhelyev M, Eichhorn ME, et al. Rapamycin induces tumor-specific thrombosis via tissue factor in the presence of VEGF. Blood 2005; 105(11): 4463-4469.
17. Dufour M, Dormond-Meuwly A, Demartines N, Dormond O. Targeting the Mammalian Target of Rapamycin (mTOR) in CancerTherapy: Lessons from Past and Future Perspectives. Cancers 2011; 3(2): 2478-2500.
18. Zoncu R, Efeyan A, Sabatini DM. MTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 2011; 12(1): 21-35.
19. Jacinto E, Lorberg A. TOR regulation of AGC kinases in yeast and mammals. Biochem J 2008; 410(1): 19-37.
20. Sarbassov DD, Ali SM, Sengupta S, et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 2006; 22(2): 159-168.
21. Manning BD, Tee AR, Logsdon MN, Blenis J, Cantley LC. Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3- kinase/akt pathway. Mol Cell 2002; 10(1): 151-162.
22. Ma L, Chen Z, Erdjument-Bromage H, Tempst P, Pandolfi PP. Phosphorylation and functional inactivation of TSC2 by Erkimplications for tuberous sclerosis and cancer pathogenesis. Cell 2005; 121(2): 179-193.
23. Inoki K, Zhu T, Guan KL. TSC2 mediates cellular energy response to control cell growth and survival. Cell 2003; 115(5): 577-590.
24. DeYoung MP, Horak P, Sofer A, Sgroi D, Ellisen LW. Hypoxia regulates TSC1/2-mTOR signaling and tumor suppression throughREDD1-mediated 14-3-3 shuttling. Genes Dev 2008; 22(2): 239-251.
25. Sancak Y, Thoreen CC, Peterson TR, et al. PRAS40 is an insulinregulated inhibitor of the mTORC1 protein kinase. Mol Cell 2007; 25(6): 903-915.
26. Sancak Y, Peterson TR, Shaul YD, et al. The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1. Science 2008; 320(5882): 1496-1501.
27. Zinzalla V, Stracka D, Oppliger W, Hall MN. Activation of mTORC2 by association with the ribosome. Cell 2011; 144(5): 757-768.
28. Gan X, Wang J, Su B, Wu D. Evidence for direct activation of mTORC2 kinase activity by phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem 2011; 286(13): 10998-10002.
29. Del Bufalo D, Ciuffreda L, Trisciuoglio D, et al. Antiangiogenicpotential of the Mammalian target of rapamycin inhibitor temsirolimus. Cancer Res 2006; 66(11): 5549-5554.
30. Phung TL, Ziv K, Dabydeen D, et al. Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin. Cancer Cell 2006; 10(2): 159-170.
31. Lane HA, Wood JM, McSheehy PM, et al. MTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor. Clin Cancer Res 2009; 15(5): 1612-1622.
32. Guimaraes AR, Ross R, Figuereido JL, Waterman P, Weissleder R. MRI with magnetic nanoparticles monitors downstream antiangiogenic effects of mTOR inhibition. Mol Imaging Biol 2011; 13(2): 314-320.
33. Mabuchi S, Altomare DA, Connolly DC, et al. RAD001 (Everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancer. Cancer Res 2007; 67(6): 2408-2413.
34. Stallone G, Schena A, Infante B, et al. Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med 2005; 352(13): 1317-1323.
35. Wang L, Shi WY, Wu ZY, et al. Cytostatic and anti-angiogenic effects of temsirolimus in refractory mantle cell lymphoma. J Hematol Oncol 2010; 3: 30.
36. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356(22): 2271-2281.
37. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008; 372(9637): 449-456.
38. Vinals F, Chambard JC, Pouyssegur J. P70 S6 kinase-mediated protein synthesis is a critical step for vascular endothelial cellproliferation. J Biol Chem 1999; 274(38): 26776-2682.
39. Xue Q, Nagy JA, Manseau EJ, Phung TL, Dvorak HF, Benjamin LE. Rapamycin inhibition of the Akt/mTOR pathway blocks select stages of VEGF-A164-driven angiogenesis, in part by blocking S6Kinase. Arterioscler Thromb Vasc Biol 2009; 29(8): 1172-1178.
40. Kanda S, Hodgkin MN, Woodfield RJ, Wakelam MJ, Thomas G, Claesson-Welsh L. Phosphatidylinositol 3'-kinase-independent p70S6 kinase activation by fibroblast growth factor receptor-1 is important for proliferation but not differentiation of endothelial cells. J Biol Chem 1997; 272(37): 23347-53.
41. Humar R, Kiefer FN, Berns H, Resink TJ, Battegay EJ. Hypoxia enhances vascular cell proliferation and angiogenesis in vitro via rapamycin (mTOR)-dependent signaling. FASEB J 2002; 16(8): 771-780.
42. Moss SC, Lightell DJ, Jr., Marx SO, Marks AR, Woods TC. Rapamycin regulates endothelial cell migration through regulation of the cyclin-dependent kinase inhibitor p27Kip1. J Biol Chem 2010; 285(16): 11991-111997.
43. Panka DJ, Mier JW. Canstatin inhibits Akt activation and induces Fas-dependent apoptosis in endothelial cells. J Biol Chem 2003; 278(39): 37632-37636.
44. Maeshima Y, Sudhakar A, Lively JC, et al. Tumstatin, an endothelial cell-specific inhibitor of protein synthesis. Science 2002; 295(5552): 140-143.
45. Mabuchi S, Altomare DA, Cheung M, et al. RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model. Clin Cancer Res 2007; 13(14): 4261-4270.
46. Wan X, Shen N, Mendoza A, Khanna C, Helman LJ. CCI-779 inhibits rhabdo myosarcoma xeno graft growth by an antiangiogenic mechanism linked to the targeting of mTOR/Hif-1alpha/VEGF signaling. Neoplasia 2006; 8(5): 394-401.
47. Forsythe JA, Jiang BH, Iyer NV, et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 1996; 16(9): 4604-4613.
48. Fang J, Yan L, Shing Y, Moses MA. HIF-1alpha-mediated upregulation of vascular endothelial growth factor, independent of basic fibroblast growth factor, is important in the switch to the angiogenic phenotype during early tumorigenesis. Cancer Res 2001; 61(15): 5731-5735.
49. Hudson CC, Liu M, Chiang GG, et al. Regulation of hypoxiainducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol Cell Biol 2002; 22(20): 7004-7014.
50. Dormond O, Contreras AG, Meijer E, et al. CD40-induced signaling in human endothelial cells results in mTORC2- and Aktdependent expression of vascular endothelial growth factor in vitro and in vivo. J Immunol 2008; 181(11): 8088-8095.
51. Lee DF, Hung MC. All roads lead to mTOR: integrating inflammation and tumor angiogenesis. Cell Cycle 2007; 6(24): 3011-3014.
52. Lee DF, Kuo HP, Chen CT, et al. IKK beta suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway. Cell 2007; 130(3): 440-455.
53. Efeyan A, Sabatini DM. MTOR and cancer: many loops in one pathway. Curr Opin Cell Biol 2010; 22(2): 169-176.
54. O'Reilly KE, Rojo F, She QB, et al. TMTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006; 66(3): 1500-158.
55. Carracedo A, Ma L, Teruya-Feldstein J, et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3Kdependent feedback loop in human cancer. J Clin Invest 2008; 118(9): 3060-3074.
56. Li W, Petrimpol M, Molle KD, Hall MN, Battegay EJ, Humar R. Hypoxia-induced endothelial proliferation requires both mTORC1 and mTORC2. Circ Res 2007; 100(1): 79-87.
57. Dada S, Demartines N, Dormond O. MTORC2 regulates PGE2-mediated endothelial cell survival and migration. Biochem Biophys Res Commun 2008; 372(4): 875-879.
58. Toschi A, Lee E, Gadir N, Ohh M, Foster DA. Differential dependence of hypoxia-inducible factors 1 alpha and 2 alpha on mTORC1 and mTORC2. J Biol Chem 2008; 283(50): 34495-34499.
59. Guertin DA, Stevens DM, Thoreen CC, et al. Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1. Dev Cell 2006; 11(6): 859-8571.
60. Eshleman JS, Carlson BL, Mladek AC, Kastner BD, Shide KL, Sarkaria JN. Inhibition of the mammalian target of rapamycinsensitizes U87 xenografts to fractionated radiation therapy. Cancer Res 2002; 62(24): 7291-7297.
61. Wu L, Birle DC, Tannock IF. Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts. Cancer Res 2005; 65(7): 2825-2831.
62. Murphy JD, Spalding AC, Somnay YR, Markwart S, Ray ME, Hamstra DA. Inhibition of mTOR radiosensitizes soft tissue sarcoma and tumor vasculature. Clin Cancer Res 2009; 15(2): 589-596.
63. Kim DD, Kleinman DM, Kanetaka T, et al. Rapamycin inhibits VEGF-induced microvascular hyperpermeability in vivo. Microcirculation 2010; 17(2): 128-136.
64. Bruns CJ, Koehl GE, Guba M, et al. Rapamycin-induced endothelial cell death and tumor vessel thrombosis potentiate cytotoxic therapy against pancreatic cancer. Clin Cancer Res 2004; 10(6): 2109-2119.
65. Barone GW, Gurley BJ, Abul-Ezz SR, Gokden N. Sirolimusinduced thrombotic microangiopathy in a renal transplant recipient. Am J Kidney Dis 2003; 42(1): 202-206.
66. Robson M, Cote I, Abbs I, Koffman G, Goldsmith D. Thrombotic micro-angiopathy with sirolimus-based immunosuppression: potentiation of calcineurin-inhibitor-induced endothelial damage? Am J Transplant 2003; 3(3): 324-327.
67. Guertin DA, Sabatini DM. The pharmacology of mTOR inhibition. Sci Signal 2009; 2(67): pe24.
68. Benjamin D, Colombi M, Moroni C, Hall MN. Rapamycin passes the torch: a new generation of mTOR inhibitors. Nat Rev Drug Discov 2011; 10(11): 868-880.
69. Schnell CR, Stauffer F, Allegrini PR, et al. Effects of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 on the tumor vasculature: implications for clinical imaging. Cancer Res 2008; 68(16): 6598-6607.
70. Falcon BL, Barr S, Gokhale PC, et al. Reduced VEGF production, angiogenesis, and vascular regrowth contribute to the antitumor properties of dual mTORC1/mTORC2 inhibitors. Cancer Res 2011; 71(5): 1573-1583.
71. Xue Q, Hopkins B, Perruzzi C, Udayakumar D, Sherris D, Benjamin LE. Palomid 529, a novel small-molecule drug, is a TORC1/TORC2 inhibitor that reduces tumor growth, tumor angiogenesis, and vascular permeability. Cancer Res 2008; 68(22): 9551-9557.
72. Raynaud FI, Eccles S, Clarke PA, et al. Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases. Cancer Res 2007; 67(12): 5840-5850.
73. Liu TJ, Koul D, LaFortune T, et al. NVP-BEZ235, a novel dualphosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas. Mol Cancer Ther 2009; 8(8): 2204-2210.
74. Yu K, Toral-Barza L, Shi C, et al. Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors ofthe mammalian target of rapamycin. Cancer Res 2009; 69(15): 6232-6240.
75. Cho DC, Cohen MB, Panka DJ, et al. The efficacy of the noveldual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared withrapamycin in renal cell carcinoma. Clin Cancer Res 2010; 16(14): 3628-3638.
76. Feldman ME, Apsel B, Uotila A, et al. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol 2009; 7(2): e38.
77. Thoreen CC, Kang SA, Chang JW, et al. An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycinresistant functions of mTORC1. J Biol Chem 2009; 284(12): 8023-8032.
78. Fokas E, Im JH, Hill SA, et al. Dual inhibition of the PI3K/mTOR pathway increases tumor radiosensitivity by normalizing tumor vasculature. Cancer Res 2011 Nov 28.